Gsk Plc Stock Fundamentals
| G1SK34 Stock | BRL 41.07 0.29 0.71% |
GSK plc fundamentals help investors to digest information that contributes to GSK Plc's financial success or failures. It also enables traders to predict the movement of GSK Stock. The fundamental analysis module provides a way to measure GSK Plc's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to GSK Plc stock.
GSK |
GSK plc Company Profit Margin Analysis
GSK Plc's Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Current GSK Plc Profit Margin | 0.51 % |
Most of GSK Plc's fundamental indicators, such as Profit Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, GSK plc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
| Competition |
Based on the latest financial disclosure, GSK plc has a Profit Margin of 0.51%. This is 104.55% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers-General industry. The profit margin for all Brazil stocks is 140.16% lower than that of the firm.
GSK plc Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining GSK Plc's current stock value. Our valuation model uses many indicators to compare GSK Plc value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across GSK Plc competition to find correlations between indicators driving GSK Plc's intrinsic value. More Info.GSK plc is one of the top stocks in return on equity category among its peers. It also is one of the top stocks in return on asset category among its peers reporting about 0.21 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for GSK plc is roughly 4.75 . Comparative valuation analysis is a catch-all model that can be used if you cannot value GSK Plc by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for GSK Plc's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.GSK Profit Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses GSK Plc's direct or indirect competition against its Profit Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of GSK Plc could also be used in its relative valuation, which is a method of valuing GSK Plc by comparing valuation metrics of similar companies.GSK Plc is currently under evaluation in profit margin category among its peers.
GSK Fundamentals
| Return On Equity | 0.31 | |||
| Return On Asset | 0.0659 | |||
| Profit Margin | 0.51 % | |||
| Operating Margin | 0.25 % | |||
| Current Valuation | 484.56 B | |||
| Shares Outstanding | 4.09 B | |||
| Price To Book | 2.60 X | |||
| Price To Sales | 9.93 X | |||
| Revenue | 34.11 B | |||
| Gross Profit | 19.92 B | |||
| EBITDA | 8.6 B | |||
| Net Income | 4.38 B | |||
| Total Debt | 19.76 B | |||
| Book Value Per Share | 5.25 X | |||
| Cash Flow From Operations | 7.95 B | |||
| Earnings Per Share | 6.69 X | |||
| Price To Earnings To Growth | 0.45 X | |||
| Number Of Employees | 10 | |||
| Beta | 0.28 | |||
| Market Capitalization | 388.07 B | |||
| Total Asset | 79.1 B | |||
| Z Score | 11.4 | |||
| Annual Yield | 0.04 % | |||
| Net Asset | 79.1 B | |||
| Last Dividend Paid | 0.61 |
About GSK Plc Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze GSK plc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of GSK Plc using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of GSK plc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in GSK Stock
GSK Plc financial ratios help investors to determine whether GSK Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in GSK with respect to the benefits of owning GSK Plc security.